Carrie E. Rubel

738 total citations
17 papers, 326 citations indexed

About

Carrie E. Rubel is a scholar working on Molecular Biology, Physiology and Psychiatry and Mental health. According to data from OpenAlex, Carrie E. Rubel has authored 17 papers receiving a total of 326 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 9 papers in Physiology and 4 papers in Psychiatry and Mental health. Recurrent topics in Carrie E. Rubel's work include Alzheimer's disease research and treatments (8 papers), Mitochondrial Function and Pathology (3 papers) and Dementia and Cognitive Impairment Research (3 papers). Carrie E. Rubel is often cited by papers focused on Alzheimer's disease research and treatments (8 papers), Mitochondrial Function and Pathology (3 papers) and Dementia and Cognitive Impairment Research (3 papers). Carrie E. Rubel collaborates with scholars based in United States, Belgium and United Kingdom. Carrie E. Rubel's co-authors include Jonathan C. Schisler, Cam Patterson, Chunlian Zhang, Pamela Lockyer, Douglas Cyr, Holly McDonough, Andrea L. Portbury, Song Tan, Chang-he Shi and Lei Xu and has published in prestigious journals such as Journal of Clinical Investigation, The FASEB Journal and Journal of the American Society of Nephrology.

In The Last Decade

Carrie E. Rubel

15 papers receiving 323 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Carrie E. Rubel United States 8 221 83 67 48 44 17 326
Daita Kaneda Japan 10 183 0.8× 79 1.0× 101 1.5× 47 1.0× 52 1.2× 39 402
Hye-Won Hyun South Korea 11 195 0.9× 89 1.1× 50 0.7× 72 1.5× 46 1.0× 13 334
Paula García-Huerta Spain 6 252 1.1× 54 0.7× 38 0.6× 26 0.5× 54 1.2× 6 492
Stefano Cattaneo Italy 10 203 0.9× 90 1.1× 122 1.8× 39 0.8× 20 0.5× 18 401
Jun‐Ge Yu United States 12 142 0.6× 111 1.3× 127 1.9× 30 0.6× 28 0.6× 17 495
Sara L. Domínguez United States 10 143 0.6× 57 0.7× 67 1.0× 16 0.3× 32 0.7× 14 337
Wenbiao Xiao China 12 245 1.1× 41 0.5× 43 0.6× 18 0.4× 38 0.9× 33 395
Pierre Chryso Djoufack Germany 5 115 0.5× 69 0.8× 64 1.0× 16 0.3× 25 0.6× 7 336
Amrita Pathak United States 12 165 0.7× 83 1.0× 48 0.7× 26 0.5× 16 0.4× 15 455
Karolina Minta Sweden 13 116 0.5× 44 0.5× 105 1.6× 24 0.5× 25 0.6× 19 293

Countries citing papers authored by Carrie E. Rubel

Since Specialization
Citations

This map shows the geographic impact of Carrie E. Rubel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carrie E. Rubel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carrie E. Rubel more than expected).

Fields of papers citing papers by Carrie E. Rubel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carrie E. Rubel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carrie E. Rubel. The network helps show where Carrie E. Rubel may publish in the future.

Co-authorship network of co-authors of Carrie E. Rubel

This figure shows the co-authorship network connecting the top 25 collaborators of Carrie E. Rubel. A scholar is included among the top collaborators of Carrie E. Rubel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carrie E. Rubel. Carrie E. Rubel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Rubel, Carrie E., et al.. (2026). A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer’s disease. The Journal of Prevention of Alzheimer s Disease. 13(2). 100458–100458.
2.
Fogelman, I., Tim West, Joel B. Braunstein, et al.. (2023). Independent study demonstrates amyloid probability score accurately indicates amyloid pathology. Annals of Clinical and Translational Neurology. 10(5). 765–778. 13 indexed citations
3.
Vanbrabant, Jeroen, Steffi De Meyer, Carrie E. Rubel, et al.. (2023). Performance of plasma pTau181 and pTau217 measured with fully automated LUMIPULSE G prototype immunoassays. Alzheimer s & Dementia. 19(S15). 1 indexed citations
4.
Vanbrabant, Jeroen, Sherif Bayoumy, Inge M.W. Verberk, et al.. (2023). Performance of optimized prototype LUMIPULSE G immunoassays for plasma pTau181 and pTau217. Alzheimer s & Dementia. 19(S24). 2 indexed citations
5.
Nisenbaum, Laura, Robert Martone, Tianle Chen, et al.. (2023). CSF biomarker concordance with amyloid PET in Phase 3 studies of aducanumab. Alzheimer s & Dementia. 19(8). 3379–3388. 6 indexed citations
6.
Kivisäkk, Pia, Becky C. Carlyle, James P. Quinn, et al.. (2022). Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer’s disease. Alzheimer s Research & Therapy. 14(1). 58–58. 54 indexed citations
7.
Aisen, Paul, Frederik Barkhof, Carmen Castrillo‐Viguera, et al.. (2022). ENVISION: A phase 3b/4 randomized, double‐blind, placebo‐controlled, parallel‐group study to verify the clinical benefit of aducanumab in participants with early Alzheimer’s disease. Alzheimer s & Dementia. 18(S10). 3 indexed citations
8.
Kivisäkk, Pia, Becky C. Carlyle, Bianca A. Trombetta, et al.. (2021). Levels of the synaptic proteins PSD‐95, SNAP‐25, and neurogranin are selectively increased in the cerebrospinal fluid of patients with Alzheimer’s disease. Alzheimer s & Dementia. 17(S5). 1 indexed citations
9.
Vanbrabant, Jeroen, Erik Stoops, Kimberley Mauroo, et al.. (2021). Development and analytical characterization of novel tau Simoa assays targeting full‐length tau in CSF and mid‐tau in CSF and plasma. Alzheimer s & Dementia. 17(S5). 1 indexed citations
10.
Patterson, Cam, Holly McDonough, Ruihao Wang, et al.. (2020). Ataxia and hypogonadism caused by the loss of ubiquitin ligase activity of the U box protein CHIP. UNC Libraries.
11.
Wu, Qi, Hanne B. Moeller, Marleen L. A. Kortenoeven, et al.. (2018). CHIP regulates Aquaporin‐2 Quality Control and Body Water Homeostasis. The FASEB Journal. 32(S1). 10 indexed citations
12.
Wu, Qi, Hanne B. Moeller, Marleen L. A. Kortenoeven, et al.. (2017). CHIP Regulates Aquaporin-2 Quality Control and Body Water Homeostasis. Journal of the American Society of Nephrology. 29(3). 936–948. 39 indexed citations
13.
Rubel, Carrie E., Sarah E. Soss, Holly McDonough, et al.. (2015). The Unfolding Tail of CHIP Mutation in Gordon Holmes Syndrome. The FASEB Journal. 29(S1). 2 indexed citations
14.
Young, Martin E., Carrie E. Rubel, Carolyn Spaniel, et al.. (2014). MuRF1 activity is present in cardiac mitochondria and regulates reactive oxygen species production in vivo. Journal of Bioenergetics and Biomembranes. 46(3). 173–187. 22 indexed citations
15.
Rubel, Carrie E., Jonathan C. Schisler, Eric D. Hamlett, et al.. (2013). Diggin′ on U(biquitin): A Novel Method for the Identification of Physiological E3 Ubiquitin Ligase Substrates. Cell Biochemistry and Biophysics. 67(1). 127–138. 13 indexed citations
16.
Schisler, Jonathan C., Carrie E. Rubel, Chunlian Zhang, et al.. (2013). CHIP protects against cardiac pressure overload through regulation of AMPK. Journal of Clinical Investigation. 123(8). 3588–3599. 54 indexed citations
17.
Shi, Chang-he, Jonathan C. Schisler, Carrie E. Rubel, et al.. (2013). Ataxia and hypogonadism caused by the loss of ubiquitin ligase activity of the U box protein CHIP. Human Molecular Genetics. 23(4). 1013–1024. 105 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daita Kaneda Breakdown of academic impact, for papers by Hye-Won Hyun Breakdown of academic impact, for papers by Paula García-Huerta Breakdown of academic impact, for papers by Stefano Cattaneo Breakdown of academic impact, for papers by Jun‐Ge Yu Breakdown of academic impact, for papers by Sara L. Domínguez Breakdown of academic impact, for papers by Wenbiao Xiao Breakdown of academic impact, for papers by Pierre Chryso Djoufack Breakdown of academic impact, for papers by Amrita Pathak Breakdown of academic impact, for papers by Karolina Minta
Rankless by CCL
2026